International Journal of Antimicrobial Agents国际抗微生物药物杂志
International Journal of Antimicrobial Agents(英文缩写 INT J ANTIMICROB AG),ISSN 0924-8579,eISSN 1872-7913,中文译名:国际抗微生物药物杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 15.441 | Q1 |
| 2022 | 10.800 | Q1 |
| 2023 | 4.900 | Q1 |
| 2024 | 4.600 | Q1 |
| 2025 | 5.000 | Q1 |
International Journal of Antimicrobial Agents 最新收录文献
-
1. Extended vs. standard bedaquiline treatment for MDR/RR-TB: A 5-year multi-centre study on clinical outcomes and cardiac safety in China.
PMID:日期:2026-10-01Multidrug-resistant and rifampin-resistant tuberculosis (MDR/RR-TB) remains a formidable challenge to global health. While the integration of bedaquiline (BDQ) has revolutionized the therapeutic landscape for MDR/RR-TB, the clinical necessity and safety profile of extending BDQ administration beyond the conventional 24-week regimen - especially in complex or high-risk cohorts - remain insufficiently characterized. This multi-centre retrospective cohort study analysed 189 patients with MDR/RR-TB in China between January 2019 and January 2024. Patients were stratified into a standard-duration group (≤6 months) and an extended-duration group (>6 months). Treatment efficacy, cumulative culture conversion rates, and adverse events were comparatively evaluated. Multivariable logistic regression was employed to identify independent predictors of severe Fridericia-corrected QT (QTcF) prolongation (>500 ms). No significant differences were observed in favourable treatment outcomes between the extended and standard groups (86.8% vs. 85.8%; P = 0.845). Culture conversion rates at the end of treatment were comparable (94.7% vs. 92.0%; P = 0.457). Regarding cardiac safety, the incidence of QTcF >500 ms did not differ significantly between the two cohorts (7.9% vs. 10.6%; P = 0.528). Notably, pre-existing cardiac disease was identified as the most potent independent risk factor for severe QTcF prolongation (OR: 9.01; 95% confidence interval: 2.53-32.12; P < 0.001), rather than the duration of BDQ exposure. Extended BDQ treatment is both efficacious and well-tolerated in patients with MDR/RR-TB. Prolonged exposure does not inherently increase the risk of cardiotoxicity, suggesting that BDQ duration can be personalized based on clinical need, provided that baseline cardiac comorbidities are rigorously managed.
-
2. Biological characterization of Candida parapsilosis haploids induced by voriconazole.
PMID:日期:2026-10-01Candida parapsilosis is an important opportunistic fungal pathogen causing serious human infections in nosocomial settings. It has long been thought that C. parapsilosis has a diploid genome with a high homozygosity between chromosome homologs. In this study, we report the discovery of C. parapsilosis haploids induced by voriconazole, a triazole with broad antifungal activity against fungal pathogens, in an experimental evolutionary assay. The haploid strains were able to undergo auto-diploidization under in vitro culture conditions or during systemic infection at a low frequency. Compared to the progenitor diploid strain, C. parapsilosis haploid and auto-diploid strains exhibited a reduced ability of invasive growth and biofilm formation. Global transcriptional expression analysis indicated that haploid and auto-diploid strains had a similar transcriptomic profile, which showed a remarkable difference from the progenitor diploid strain perhaps due to the loss of chromosome heterozygosity. Moreover, the haploid and diploid strains had distinct fungal burdens in different animal tissues, suggesting the haploid state could have a colonization advantage over the diploids in certain tissues such as the brain and spleen. The discovery of C. parapsilosis haploids not only sheds lights on the biology of this important fungal pathogen, but also provides a tool for genetic modifications for the field.
-
4. Broad-spectrum empirical antibiotic overuse in community-onset bacteraemia: Prevalence, outcomes, and associated factors.
PMID:日期:2026-10-01Empirical broad-spectrum antibiotic overuse in community-onset (CO) bacteraemia poses significant clinical risks. We evaluated the prevalence and risk factors of excessively broad-spectrum empirical antibiotic use and its association with clinical outcomes. This retrospective cohort study included 11 183 inpatients diagnosed with CO bacteraemia. CO bacteraemia was further classified as community-acquired (CA) bacteraemia or healthcare-associated (HCA) bacteraemia. Excessively broad-spectrum antibiotic use was defined as empirical broad-spectrum antibiotic administration without isolating a compatible resistant pathogen, and clinical characteristics and outcomes were compared according to that status using inverse probability of treatment weighting-adjusted logistic regression. Among all eligible patients, adequate empirical antibiotics were administered to 9343 (83.5%) patients; however, 6944 (62.1%) were administered excessively broad empirical antibiotics - 4040 (63.5%) among HCA patients and 2904 (60.2%) among CA patients. Despite high rate of broad-spectrum empirical antibiotics prescribing (69.9% of CA patients and 81.5% of HCA patients), resistant organisms were microbiologically confirmed in only 24.1% of CA patients and 43.1% of HCA patients. Cancer, higher Pitt bacteraemia scores, and inotropics use were independently associated with excessively broad-spectrum empirical antibiotic administration. Infection sources were also associated with prescribing patterns, and broad-spectrum antibiotic use was more likely in lower respiratory tract and intra-abdominal infections. Excessive use was associated with adverse outcomes, including in-hospital mortality (adjusted odds ratio 1.57; 95% confidence interval, 1.16-2.11) and Clostridioides difficile infection (adjusted odds ratio 1.72; 95% confidence interval, 1.08-2.74). Excessively broad empirical antibiotic use was prevalent and associated with adverse clinical outcomes in CO bacteraemia, underscoring the need for enhanced antimicrobial stewardship.
-
5. Lactobacillus rhamnosus-derived postbiotics inhibit proliferation, invasion, and EMT-associated signalling in colorectal cancer cells.
PMID:日期:2026-10-01Probiotics and their metabolites (postbiotics) have gained increasing attention because of their potential anticancer properties. This study aimed to evaluate the effects of postbiotics derived from Lactobacillus rhamnosus (LR) on colorectal cancer (CRC) cells and to investigate their potential effects on malignant phenotypes and epithelial-mesenchymal transition (EMT)-associated signalling. Sterile LR culture filtrates were applied to SW480 colorectal cancer cells and highly invasive SW480-I5 cells. Cell viability, proliferation, migration, invasion, and apoptosis were assessed. The expression of EMT-associated transcription factors, mesenchymal markers, and matrix metalloproteinase 3 (MMP3) was also evaluated to explore the underlying molecular mechanisms. LR culture filtrates reduced cell viability in a dose-dependent manner and significantly suppressed cell migration and invasion, with more pronounced effects observed in highly invasive SW480-I5 cells. LR treatment also inhibited cell proliferation and promoted apoptosis in both cell lines. Mechanistically, LR filtrates downregulated the EMT-associated transcription factors ZEB2, Snail, and Twist, as well as the mesenchymal markers N-cadherin and Vimentin, and reduced MMP3 expression. LR-derived postbiotics exert inhibitory effects on CRC-associated malignant phenotypes by suppressing cell viability, proliferation, migration, and invasion while promoting apoptosis and modulating EMT-associated signalling. These findings suggest that LR-derived postbiotics may represent promising adjunctive candidates for CRC modulation.
-
6. Missed opportunities for antibiotic de-escalation among clinically stable adult patients with bloodstream infection: Secondary analysis of a prospective, multicentre study.
PMID:日期:2026-10-01Antibiotic de-escalation (ADE) is a key antimicrobial stewardship quality indicator. We aimed to evaluate the rate and patterns of ADE among clinically stable patients with bloodstream infection. We analysed secondary data from two prospective multicentre cohort studies, BLOOMY and BLOOMY-PREDICT. ADE was assessed among patients eligible for safe ADE on day 5 after index blood culture. Narrowing of antibiotic spectrum was determined by a ranking based on WHO AWaRe-classification. Risk factors for not performing ADE (non-ADE) were studied using multivariable logistic regression. In total, 937 of 3824 study patients (24.50%) were eligible, of which 218 (23.27%) did not have an option for de-escalation based on antimicrobial susceptibility testing. Of 719 patients in which ADE was feasible, only 406 (56.47%) received ADE. Empiric monotherapy (OR [95% CI] = 5.68 [3.77-8.56], P < 0.001), Gram-negative pathogen (OR 2.27 [1.60-3.24], P < 0.001), healthcare-associated infection (OR 1.55 [1.01-2.39], P = 0.046), and hospital-acquisition (OR 1.63 [1.02-2.61], P = 0.042) were identified as independent factors associated with non-ADE. Conversely, ICU treatment on day 0 (OR 0.60 [0.38-0.95], P = 0.029) was independently associated with de-escalation, alongside a strong study centre effect (OR 0.26 [0.15-0.44], P < 0.001). Further, in-hospital mortality was not associated with ADE (46/406, 11.33% vs. 29/313, 9.27%, P = 0.369). Low ADE rates in patients with urogenital focus and unnecessary carbapenem use were issues of particular concern in our cohort. Available opportunities for ADE were frequently missed in our setting, especially in Gram-negative bloodstream infection. Antimicrobial stewardship efforts should therefore be strengthened to promote ADE.
-
8. Clinical characteristics and therapeutic dilemmas in nocardiosis: Insights from a case series.
PMID:日期:2026-10-01Nocardiosis often requires prolonged antimicrobial therapy, and trimethoprim-sulfamethoxazole (TMP-SMX) is considered the cornerstone of treatment. However, TMP-SMX-related adverse events frequently complicate long-term therapy, and real-world data regarding treatment continuity and outcomes remain limited. We conducted a retrospective observational study of patients with Nocardia species isolated from clinical specimens at a tertiary-care academic hospital in Japan between January 2015 and April 2025. Clinical characteristics, antimicrobial therapy, adverse events, and outcomes were reviewed. Eleven cases were enrolled, with a median age of 65 years. The cohort comprised seven patients with severe nocardiosis (disseminated disease, brain abscess, and pneumonia in transplant recipients) and four patients with mild nocardiosis (cutaneous infection and pneumonia). Nine patients received TMP-SMX as part of the initial regimen, of whom seven required modification of therapy within 1 day to 3 months because of adverse events. Following modification of TMP-SMX, patients were treated with alternative regimens, including fluoroquinolone-and minocycline-based therapies, as well as β-lactam-containing combinations. Importantly, no cases of treatment failure or death were observed, and no relapses were identified during the available follow-up period, even among patients with those clinically complex diseases. Although TMP-SMX is the first-line therapy for nocardiosis, the majority of our patients did not tolerate the drug. Nevertheless, favorable outcomes were observed with alternative regimens, even in patients with clinically complex disease, suggesting that alternative regimens may be reasonable options when TMP-SMX is not tolerated.
-
9. CABO-CHANCE study: A real-life world study of cabotegravir plus rilpivirine long-acting intramuscular in ART-experienced people with HIV.
9. CABO-CHANCE研究：一项关于卡博替拉韦联合利匹韦林长效肌内注射抗逆转录病毒治疗经验丰富的艾滋病毒感染者的现实世界研究PMID:日期:2026-10-01This study of people with HIV (PWH) receiving CAB + RPV LAI evaluated its effectiveness, safety, and impact on inflammatory markers, body fat/lean mass distributions, quality of life, sleep, health satisfaction, and stigma experience over 1 y. A prospective, longitudinal, multicentre study was conducted in 15 hospitals and enrolled between June 2023 and January 2024. It included virologically suppressed PWH (HIV-1 RNA <50 c/mL for ≥6 months) switched from oral antiretroviral therapy to CAB + RPV LAI. Anthropometrics, CD4/CD8 counts, viral load, creatinine clearance, lipid levels, and inflammatory markers were recorded at baseline and 12, 28, 52 weeks. Patient-reported outcomes were gathered using the WHOQOL-HIV-BREF, HIV stigma scale for use in Spain, Pittsburgh Sleep Quality Index, and questionnaires on health satisfaction and adverse events. A subpopulation underwent to whole-body dual energy X-ray absorptiometer (DEXA). Among 269 PWH (mean age 45.6 y; 89.2% male), 240 completed 52-week follow-up, 14 (5.2%) were lost to follow-up, six (2.2%) withdrew consent, 5 (1.9%) were discontinued for adverse events, and one (0.4%) had virological failure (week 12). Snapshot effectiveness was 88.8% (intention-to-treat) and 97.5% (per-protocol). No oral bridging was required. CD4/CD8 ratio (P = 0.0001) and creatinine clearance (P = 0.0001) increased, d-dimer decreased at week 12 (P = 0.001), and BMI modestly increased (P = 0.046). No changes in total/regional fat or lean mass by DEXA (n = 56). Stigma (P = 0.029) and adverse events (P = 0.001) improved. In this real-world cohort, CAB + RPV LAI was highly effective and safe, was associated with a possible favourable immunologic response, a transient reduction in inflammation, and reduced perceived stigma over 1 y.
-
10. Arginine metabolism and compensatory adaptations expand the impaired phage resistance repertoire in colistin-resistant Acinetobacter baumannii.
PMID:日期:2026-10-01Limiting the emergence of phage resistance is a key priority in optimizing phage therapy. However, it remains poorly understood whether the development of antibiotic resistance influences the evolution of phage resistance. To investigate phage-host interactions, we used both colistin-resistant strains derived from the wild-type and genetically engineered knockout mutants. Transcriptomic analysis was employed to examine the adaptive responses of these colistin-resistant mutants under phage pressure. Finally, we characterized the phage-resistant variants that evolved in the colistin-resistant backgrounds. Our results demonstrate that the emergence of phage-resistant variants was significantly reduced in colistin-resistant mutants. These phenotypic changes were primarily mediated by disruption of lpxC and lpxD, with additional effects from compensatory mutations and amino acid metabolism. The ΔlpxC and ΔlpxD mutants exhibited distinct transcriptional profiles and metabolic features under phage pressure. The astA-mediated arginine metabolism pathway was a key modulator of phage-colistin-resistant mutant interactions. In the ΔlpxD background, Mla system inactivation and arginine supplementation accelerated the phage resistance evolution (including via the mucoid phenotype). Capsule defects arising during phage resistance development in both ΔlpxC and ΔlpxD mutants simultaneously increased colistin susceptibility. Overall, lpxC/lpxD disruption constrains phage resistance evolution in Acinetobacter baumannii. Compensatory mutation and bacterial metabolism not only mitigate fitness cost and maintain antimicrobial resistance but also expand evolutionary trajectories of bacteria under phage pressure. These findings reveal the adaptive mechanisms of colistin-resistant A. baumannii under phage selection and support the optimization of phage therapy.